STEPHANIE GIESLER: Open Payments
NPI 1750845954 · WATERLOO, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 200 payments from 11 companies in 2025. Trend: 2023 $1,257 · 2024 $1,742 · 2025 $1,719
Food & beverage: $1,608Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 66 | $356 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $350 |
| Neurocrine BioSciences, Inc. | 37 | $223 |
| Janssen Pharmaceuticals, Inc | 34 | $196 |
| Alkermes, Inc. | 19 | $192 |
| Teva Pharmaceuticals USA, Inc. | 10 | $190 |
| Otsuka America Pharmaceutical, Inc. | 5 | $86 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, INVEGA SUSTENNA, ARISTADA, REXULTI, AUSTEDO XR, FANAPT.
Industry payments across IA — which companies pay providers there.
